N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro

被引:11
|
作者
Lackner, Michaela [1 ]
Roessler, Annika [2 ]
Volland, Andre [2 ]
Stadtmueller, Marlena Nastassja [3 ]
Muellauer, Brigitte [2 ]
Banki, Zoltan [2 ]
Stroehle, Johannes [1 ]
Luttick, Angela [4 ]
Fenner, Jennifer [4 ]
Sarg, Bettina [5 ]
Kremser, Leopold [6 ]
Tone, Paul [6 ]
Stoiber, Heribert [2 ]
von Laer, Dorothee [2 ]
Wolff, Thorsten [3 ]
Schwarz, Carsten [7 ]
Nagl, Markus [1 ]
机构
[1] Med Univ Innsbruck, Inst Hyg & Med Microbiol, Schopfstr 41, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Inst Virol, Innsbruck, Austria
[3] Robert Koch Inst, Unit Influenza & Other Resp Viruses 17, Berlin, Germany
[4] 360Biolabs Pty Ltd, Melbourne, Vic, Australia
[5] Med Univ Innsbruck, Bioctr, Inst Med Biochem, Innsbruck, Austria
[6] Innovat Biomed Concepts Inc, Staten Isl, NY USA
[7] Pediat Clin Westbrandenburg, Div Cyst Fibrosis, CF Ctr Westbrandenburg, Potsdam, Germany
关键词
N-chlorotaurine; COVID-19; influenza; respiratory syncytial virus; antiviral; anti-infective; antiseptic; respiratory tract; TAURINE CHLORAMINE; HYPOCHLOROUS ACID; NVC-422; CHLORINATION; NEUTROPHILS; EFFICACY; THERAPY; SODIUM;
D O I
10.1080/22221751.2022.2065932
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
N-chlorotaurine (NCT) a long-lived oxidant generated by leukocytes, can be synthesized chemically and applied topically as an anti-infective to different body sites, including the lung via inhalation. Here, we demonstrate the activity of NCT against viruses causing acute respiratory tract infections, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza viruses, and respiratory syncytial virus (RSV). Virucidal activity of NCT was tested in plaque assays, confirmed by RT-qPCR assays. Attack on virus proteins was investigated by mass spectrometry. NCT revealed broad virucidal activity against all viruses tested at 37 degrees C and pH 7. A significant reduction in infectious particles of SARS-CoV-2 isolates from early 2020 by 1 log(10) was detected after 15 min of incubation in 1% NCT. Proteinaceous material simulating body fluids enhanced this activity by transchlorination mechanisms (1 -2 log(10) reduction within 1-10 min). Tested SARS-CoV-2 variants B.1.1.7 (Alpha) und B.1.351 (Beta) showed a similar susceptibility. Influenza virus infectious particles were reduced by 3 log(10) (H3N2) to 5 log(10) (H1N1pdm), RSV by 4 log(10) within a few min. Mass spectrometry of NCT-treated SARS-CoV-2 spike protein and 3C-like protease, influenza virus haemagglutinin and neuraminidase, and RSV fusion glycoprotein disclosed multiple sites of chlorination and oxidation as the molecular mechanism of action. Application of 1.0% NCT as a prophylactic and therapeutic strategy against acute viral respiratory tract infections deserves comprehensive clinical investigation.
引用
收藏
页码:1293 / 1307
页数:15
相关论文
共 50 条
  • [1] Liquid Chalk Is an Antiseptic against SARS-CoV-2 and Influenza A Respiratory Viruses
    McAuley, Julie L.
    Deerain, Joshua M.
    Hammersla, William
    Aktepe, Turgut E.
    Purcell, Damian F. J.
    Mackenzie, Jason M.
    Frieman, Matthew B.
    MSPHERE, 2021, 6 (03)
  • [2] Dynamics of respiratory viruses other than SARS-CoV-2 during the COVID-19 pandemic in Madrid, Spain
    Branas, Patricia
    Munoz-Gallego, Irene
    Espartosa, Elena
    Moral, Noelia
    Abellan, Guadalupe
    Folgueira, Lola
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2023, 17 (09)
  • [3] Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease Running title: Propolis against SARS-CoV-2 infection and COVID-19
    Berretta, Andresa Aparecida
    Duarte Silveira, Marcelo Augusto
    Capcha, Jose Manuel Condor
    De Jong, David
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 131
  • [4] Vaccine against COVID-19 or against SARS-CoV-2 infection?
    Rieske, Piotr
    ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY, 2020, 7 (03) : 131 - 145
  • [5] Candidate drugs against SARS-CoV-2 and COVID-19
    McKee, Dwight L.
    Sternberg, Ariane
    Stange, Ulrike
    Laufer, Stefan
    Naujokat, Cord
    PHARMACOLOGICAL RESEARCH, 2020, 157
  • [6] An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
    Pascual-Iglesias, Alejandro
    Canton, Javier
    Ortega-Prieto, Ana Maria
    Jimenez-Guardeno, Jose M.
    Regla-Nava, Jose Angel
    PATHOGENS, 2021, 10 (08):
  • [7] Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19
    Bridges, James P.
    Vladar, Eszter K.
    Huang, Hua
    Mason, Robert J.
    THORAX, 2022, 77 (02) : 203 - 209
  • [8] Preventive Medicinal Plants and their Phytoconstituents against SARS-CoV-2/COVID-19
    Nema, Neelesh Kumar
    Mamdapur, Ghouse Modin Nabeesab
    Sarojam, Smitha
    Khamborkar, Swapnil Devidas
    Sajan, Linson Cheruveettil
    Sabu, Sachithra
    Chacko, Baby Kumaranthara
    Jacob, Viju
    PHARMACOGNOSY RESEARCH, 2021, 13 (04): : 173 - 191
  • [9] SARS-CoV-2 (COVID-19) and cystic fibrosis
    Stanton, Bruce A.
    Hampton, Thomas H.
    Ashare, Alix
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2020, 319 (03) : L408 - L415
  • [10] COVID-19: implications of SARS-CoV-2 in Colombia
    Almeida-Espinosa, Alexander
    Sarmiento-Ardila, Jorge A.
    GACETA MEDICA DE MEXICO, 2020, 156 (04): : 334 - 338